Numab's Pipeline To Benefit From Intarcia Licensing Its ND016

 
• By Sten Stovall

Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.

Nerve cells
Numab develops next-generation multispecific antibody-based immunotherapies • Source: Shutterstock

More from Deals

More from Business